AAVantgarde Gains FDA Orphan Status for Stargardt Drug
October 2, 2025
AAVantgarde Bio, a clinical-stage biotechnology company developing gene therapies for inherited retinal diseases, announced that the U.S. Food and Drug Administration (FDA) has granted AAVB-039,